top of page
Latest News
Search
Awarded 2022 NIH/NCI R01 Grant
Humbled and thrilled to receive our NIH/NCI R01 grant! It is a 5-year $3.07M grant for a prospective clinical trial with our E-Slice assay to predict Triple Negative Breast Cancer patient treatment responses to standard of care. Huge thanks to collaborators Dr. Kyuson Yun, Houston Methodist/Weill-Cornell Med, and Dr. Naoto Ueno at MD Anderson Cancer Center. #E-Slice #NIH #NCI # R01 #TNBC #MDACC #HMRI #Breastcancer #Immunotherapy #Cancertreatment #Precisiononcology
Sep 24, 20221 min read
Â


AACR 2022 mini-symposium
EMPIRI's co-founder Dr. Kyuson Yun will be presenting at the AACR, mini-symposium session "Ex Vivo Models for Understanding Genetic Variation, Metastasis, and Treatment Sensitivity" on our platform technology, "E-slice: A novel 3D culture platform for precision medicine". #medicine #technology #culture #precisionmedicine #precisiononcology #cancerdiagnostics #aacr #drugdevelopment #drugdiscovery #pharmaceutical
Feb 2, 20221 min read
Â


10x Genomics Certified Service Provider
Unparalleled expertise meets breakthrough technology! 10x Genomics is known world-wide for their single cell sequencing technologies, which are taking over the scientific world. EMPIRI is now a 10x Genomics Certified Service Provider for #singlecell analysis . We specialize in clinical sample analysis, including biopsy cores from clinical trials. Combining single-cell analysis with E-slice treatment response measurements can provide unprecedented insights into your clinical
Jul 30, 20211 min read
Â
bottom of page
